文献速递白血病淋巴瘤

RNA测序用于儿童急性淋巴细胞白血病的诊断与基因组分类

The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究对126例临床服务的ALL患者进行RNA-seq,评估其纳入标准诊疗流程以检测基因重排和IKZF1缺失的效用。RNA-seq识别了标准诊断检测到的86%的重排,并在9例标准分子评估无法分类的患者中发现了未被检出的重排。研究表明RNA-seq可在个体临床服务中实施,以增强ALL的分子诊断风险分类。

要点

  • RNA-seq可检测标准诊断遗漏的重排,尤其适用于分子分型不明的患者。
  • KMT2A重排因低表达最易被RNA-seq漏检,需结合其他方法。
  • RNA-seq可识别Ph样B-ALL并发现T-ALL中具有临床意义的新融合。

核心结论

  • RNA-seq可在个体临床服务中实施,增强当前ALL的分子诊断风险分类。

研究设计与样本

  • 研究对来自临床服务的126例ALL患者进行RNA-seq,测试其检测基因重排和IKZF1缺失的效用。

主要发现

  • RNA-seq识别了标准诊断检测到的86%的重排。
  • KMT2A重排通常可识别,但因低表达成为RNA-seq最常漏检的重排。
  • RNA-seq在9例标准检测未检出重排的患者中发现了重排,这些患者用标准分子评估无法分类。
  • T-ALL是新型基因融合的丰富来源,具有临床意义或揭示疾病生物学。

关键数值与推荐

  • 开发了从RNA-seq数据检测最常见IKZF1缺失的方法,并用RQ-PCR验证。
  • 应用表达分类器识别费城染色体样B-ALL患者。

临床怎么用

  • RNA-seq可作为标准诊疗诊断流程的补充,用于检测基因重排和IKZF1缺失。
  • 对标准分子评估无法分类的ALL患者,应考虑RNA-seq以发现潜在驱动重排。

局限性

  • KMT2A重排因低表达易被RNA-seq漏检,可能需其他方法补充。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, and implementation of risk-adapted therapy has been instrumental in the dramatic improvements in clinical outcomes. A key to risk-adapted therapies includes the identification of genomic features of individual tumors, including chromosome number (for hyper- and hypodiploidy) and gene fusions, notably ETV6-RUNX1, TCF3-PBX1, and BCR-ABL1 in B-cell ALL (B-ALL). RNA-sequencing (RNA-seq) of large ALL cohorts has expanded the number of recurrent gene fusions recognized as drivers in ALL, and identification of these new entities will contribute to refining ALL risk stratification. We used RNA-seq on 126 ALL patients from our clinical service to test the utility of including RNA-seq in standard-of-care diagnostic pipelines to detect gene rearrangements and IKZF1 deletions. RNA-seq identified 86% of rearrangements detected by standard-of-care diagnostics. KMT2A (MLL) rearrangements, although usually identified, were the most commonly missed by RNA-seq as a result of low expression. RNA-seq identified rearrangements that were not detected by standard-of-care testing in 9 patients. These were found in patients who were not classifiable using standard molecular assessment. We developed an approach to detect the most common IKZF1 deletion from RNA-seq data and validated this using an RQ-PCR assay. We applied an expression classifier to identify Philadelphia chromosome-like B-ALL patients. T-ALL proved a rich source of novel gene fusions, which have clinical implications or provide insights into disease biology. Our experience shows that RNA-seq can be implemented within an individual clinical service to enhance the current molecular diagnostic risk classification of ALL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Brown LM, Lonsdale A, Zhu A, et al. The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia. Blood Adv. 2020. PMID: 32150610. doi:10.1182/bloodadvances.2019001008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。